Analysis-Trump's antitrust enforcers 'get out of the way' of multibillion-dollar deals

The Trump administration's antitrust enforcers are significantly accelerating M&A approvals, marking a distinct departure from the previous administration's approach. The DOJ and FTC, under new leadership, cleared $63 billion in deals in June, including Mars' $36 billion acquisition of Kellanova and Omnicom's $13.5 billion Interpublic takeover, and settled with Hewlett Packard Enterprise on its $14 billion Juniper Networks deal after initially suing. This shift prioritizes allowing pro-competitive or neutral transactions to proceed quickly, evidenced by a return to shortened waiting periods and a willingness to settle, thereby providing greater certainty for dealmakers and potentially boosting megadeal activity across various sectors.

Analysis

A significant policy shift in U.S. antitrust enforcement is underway, creating a more favorable environment for M&A activity. Under new leadership, the Department of Justice and Federal Trade Commission have demonstrated a clear preference for settling cases rather than blocking deals, as evidenced by the recent clearance of three transactions worth a combined $63 billion in June. Key examples include the approval of Mars' $36 billion acquisition of Kellanova and the settlement with Hewlett Packard Enterprise over its $14 billion purchase of Juniper Networks, a deal the DOJ had previously sued to block. This new approach, which contrasts sharply with the prior administration's deterrence-focused strategy, reduces regulatory uncertainty and timelines for dealmakers. The reinstatement of shortened 30-day review periods for over 100 transactions further underscores this commitment to expediting non-problematic deals, potentially unlocking value in companies involved in pending M&A and encouraging a new wave of large-scale transactions.

Key Decisions for Investors

• Investors engaged in merger arbitrage should re-evaluate risk spreads on announced deals, as the probability of regulatory approval or settlement has materially increased, potentially shortening holding periods and improving returns.
• Consider screening for potential acquisition targets in industries ripe for consolidation, as the more lenient regulatory stance may embolden companies to pursue strategic megadeals that were previously considered too risky from an antitrust perspective.
• For pending deals like UnitedHealth's acquisition of Amedisys, the analytical focus should shift towards the viability of potential settlements, such as divestitures or licensing agreements, which the HPE-Juniper case establishes as a clear precedent for resolving competitive concerns.